Swiss drugmaker Lonza sees no delays for its project to make Moderna’s COVID-19 vaccine candidate and has “strong support” from U.S. President Donald Trump to get the necessary manufacturing equipment, its chairman said. Chairman Albert Baehny had earlier raised concerns that hiring qualified staff and finding gear like bioreactors on short notice could snarl aggressive goals to begin commercial manufacturing of vaccine ingredients for Moderna. Lonza is readying production of smaller batches this month for Moderna’s mRNA vaccine trials in 30,000 people. …read more
Source:: Yahoo Finance
